However, patients with iCRVO not only have a high risk for the development of NVG, but they also frequently suffer from macular oedema, which is now frequently treated with anti-VEGF agents, such as off-label bevacizumab, or with ranibizumab (Lucentis®) or aflibercept (Eylea®) after marketing authorisation for the treatment of macular oedema after CRVO [22, 45]. This evidence concerns the gene VEGFA and macular retinal edema.